Kate Therapeutics Debuts With $51 Million Series A to Develop Next-Generation Genetic Medicines to Treat Muscle and Heart Diseases
Retrieved on:
Thursday, June 8, 2023
Tissue, Heart, Versant, Capsid, Broad Institute, University, DM1, Pardis Sabeti, Cardiac muscle, Research, MIT, FSHD, RNA, Harvard University, AAV, Facioscapulohumeral muscular dystrophy, Patient, Machine learning, SAN, Cellular Dynamics International, Therapy, X-linked myotubular myopathy, Safety, Pharmaceutical industry, Vaccine, Cell
SAN DIEGO, June 8, 2023 /PRNewswire/ -- Kate Therapeutics Inc. ("KateTx"), a next-generation gene therapy company, today emerged from stealth mode with a $51 million Series A financing co-led by founding investor Westlake Village BioPartners and Versant Ventures, with participation from Osage University Partners and UF Innovate | Ventures. In addition, the company has granted Astellas Pharma Inc. an exclusive, worldwide license to develop, manufacture and commercialize KT430 to treat X-linked myotubular myopathy (XLMTM), the details of which are described in a separate press release issued today.
Key Points:
- "We are excited to announce KateTx's launch and what this means for patients suffering from muscle and heart diseases," said Kevin Forrest, Ph.D., president, CEO and a director of KateTx.
- "KateTx is applying novel capsid and cargo technology platforms to enable skeletal and cardiac muscle targeting and liver de-targeting.
- KateTx's current focus is identifying and advancing clinical candidates for DM1 and FSHD, as well as for other genetic muscle and heart diseases.
- "With this Series A financing and licensing agreement, KateTx will be able to progress its deep pipeline of internal programs."